WASHINGTON, D.C. -- The U.S. Congress recently approved $15 million in new funds to treat several little-known but debilitating diseases affecting impoverished populations around the globe. More than 350 million people have been disabled or severely impaired by the targeted diseases, which include leprosy, elephantiasis, snail fever, river blindness, blinding trachoma and intestinal parasites. Many more are and will soon become infected with these diseases, which contribute to poverty, social inequality and diminished productivity, at a cost of more than $10 billion annually.
"Congress has taken a bold step. Fighting these diseases won't win legislators many votes or make front page news," stated Dr. Nils Daulaire, president and CEO of the Global Health Council. "But this important initiative directly targets the suffering and disability of many of the world's forgotten children and families."
The new funds provide vital support to expand the reach of life-saving public-private partnerships between global pharmaceutical companies GlaxoSmithKline, Merck, Novartis, and Pfizer -- that have committed to donating the medicines to treat the diseases -- and a host of local and international agencies and governments. U.S. funds will be used to extend and improve coordination of the treatment delivery systems needed to get medicines to those in need.
"These new resources will not only provide the much needed treatment of disease," added Paula Luff, senior director of international philanthropy at Pfizer Inc, "They affirm the value of public private partnerships and provide hope to hundreds of health workers and patients combating these diseases each day."
The Global Health Council is the world's largest membership alliance dedicated to saving lives by improving health throughout the world. The Council serves and represents thousands of public health professionals from more than 100 countries on six continents. Members of the neglected diseases workgroup of the Council's Infectious Diseases Network include American Leprosy Missions, Global Alliance to Eliminate Lymphatic Filariasis, Human Hookworm Vaccine Initiative, International Trachoma Initiative, Mectizan Donation Program, Partners for Parasite Control, and the Schistosomiasis Control Initiative.
Source: Global Health Council
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.